Antiviral Molnupiravir Does Not Decrease Deaths or Hospital

A Lancet study has found that antiviral molnupiranir (taken as an 800mg dose twice daily for five days) does not decrease deaths or hospital admissions among patients with Covid-19 infection who are vaccinated and at higher risk of mortality. �� Antiviral Molnupiravir Does Not Decrease Deaths or Hospital Admission Among Vaccinated COVID-19 Patients: Lancet Study.

Related Keywords

New Delhi , Delhi , India , Hyderabad , Andhra Pradesh , United Kingdom , Haryana , Chris Butler , University Of Oxford , Amidst Concerns , Corbevax Booster Offers Maximum Protection , Professor Chris Butler , Haryana Health Department Asks Civil Surgeons , Coronavirus Related Measures Across All Health , Antiviral , Coronavirus , Covid , Covid 19 , Covid 19 Infection , Covid 19 Patients , Lancet Study , Molnupiranir , Molnupiranir In Covid ,